Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 19.2% in February

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 90,600 shares, a growth of 19.2% from the February 13th total of 76,000 shares. Based on an average daily trading volume, of 102,400 shares, the short-interest ratio is presently 0.9 days. Currently, 1.1% of the shares of the stock are short sold.

Avalo Therapeutics Stock Up 1.0 %

NASDAQ:AVTX opened at $7.77 on Wednesday. The company has a 50-day moving average price of $7.40 and a 200-day moving average price of $9.12. Avalo Therapeutics has a 12 month low of $4.35 and a 12 month high of $34.46.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP bought a new stake in Avalo Therapeutics during the 4th quarter valued at about $114,000. Walleye Capital LLC purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $145,000. Northern Trust Corp purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $168,000. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $446,000. 87.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wedbush assumed coverage on shares of Avalo Therapeutics in a report on Friday, February 21st. They issued an “outperform” rating and a $18.00 price target on the stock. BTIG Research started coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $35.33.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.